US Health Institute’s Genetic Research Launches New Patient Portal
|
By LabMedica International staff writers Posted on 10 Nov 2014 |
A new portal created for patients to enter health history has been designed to provide a new opportunity for investigators to obtain a better determination of the human genome.
The Clinical Genome Resource (ClinGen), a US National Institutes of Health (NIH; Bethesda, MD, USA)-funded resource focused on analyzing data from thousands of clinical genetics tests yearly, announced the launch of a new patient portal, GenomeConnect.
GenomeConnect was developed by a team of Geisinger Health System (Danville, PA, USA) investigators and collaborators from the ClinGen project to establish an online patient community, where people who previously had genetic testing can input their test results for analysis by the ClinGen team. The online portal strengthens the ClinGen laboratory database (ClinVar) by combining patient-entered health information with clinical laboratory data for a comprehensive database that helps clinicians and researchers better understand genetic variants and their impact on health. GenomeConnect also allows patients who underwent genetic testing to interact with each other in a secure online community.
“A data repository, even one as robust as ClinGen, is just the first piece of the pie when it comes to fully understanding the role genetics play in the prevention of disease and the development of treatments and therapies,” said Andrew Faucett, director of policy and education, Geisinger Health System. “By allowing patients to input additional medical information, GenomeConnect is designed to empower patients and allow them to contribute to our understanding of the human genome. Together with patients, we can learn more about the human genome and the ability to re-establish contact with patients and request additional information about their health information is critical to the clinical use of genetic testing.”
The Geisinger Genomic Council encourages the use of reference laboratories that have pledged to contribute past, present, and future genomic data to US databases in an effort to increase medical knowledge and optimize patient care. “In order to advance patient care and continue genomic work to help improve the interpretation of genetic variants, it is vital that data from clinical testing be made publicly available while simultaneously respecting patient confidentiality,” said Christa Lese Martin, a lead investigator of the ClinGen project and director of the Autism & Developmental Medicine Institute at Geisinger. “GenomeConnect honors both of these pledges and will pay long-term dividends in patient care by developing an unrivaled database of genetic and clinical information.”
Patient portals such as GenomeConnect make genomic discoveries possible by integrating data from a large number of patients. The project is enrolling an unlimited number of participants with genetic test results and their family members, and participation takes place completely online using a computer, smartphone, or tablet.
Geisinger Health System is an integrated health services organization recognized for its innovative use of the electronic health record (EHR), and the development of new care models such as ProvenHealth Navigator and ProvenCare.
Related Links:
Clinical Genome Resource
US National Institutes of Health
GenomeConnect patient portal
The Clinical Genome Resource (ClinGen), a US National Institutes of Health (NIH; Bethesda, MD, USA)-funded resource focused on analyzing data from thousands of clinical genetics tests yearly, announced the launch of a new patient portal, GenomeConnect.
GenomeConnect was developed by a team of Geisinger Health System (Danville, PA, USA) investigators and collaborators from the ClinGen project to establish an online patient community, where people who previously had genetic testing can input their test results for analysis by the ClinGen team. The online portal strengthens the ClinGen laboratory database (ClinVar) by combining patient-entered health information with clinical laboratory data for a comprehensive database that helps clinicians and researchers better understand genetic variants and their impact on health. GenomeConnect also allows patients who underwent genetic testing to interact with each other in a secure online community.
“A data repository, even one as robust as ClinGen, is just the first piece of the pie when it comes to fully understanding the role genetics play in the prevention of disease and the development of treatments and therapies,” said Andrew Faucett, director of policy and education, Geisinger Health System. “By allowing patients to input additional medical information, GenomeConnect is designed to empower patients and allow them to contribute to our understanding of the human genome. Together with patients, we can learn more about the human genome and the ability to re-establish contact with patients and request additional information about their health information is critical to the clinical use of genetic testing.”
The Geisinger Genomic Council encourages the use of reference laboratories that have pledged to contribute past, present, and future genomic data to US databases in an effort to increase medical knowledge and optimize patient care. “In order to advance patient care and continue genomic work to help improve the interpretation of genetic variants, it is vital that data from clinical testing be made publicly available while simultaneously respecting patient confidentiality,” said Christa Lese Martin, a lead investigator of the ClinGen project and director of the Autism & Developmental Medicine Institute at Geisinger. “GenomeConnect honors both of these pledges and will pay long-term dividends in patient care by developing an unrivaled database of genetic and clinical information.”
Patient portals such as GenomeConnect make genomic discoveries possible by integrating data from a large number of patients. The project is enrolling an unlimited number of participants with genetic test results and their family members, and participation takes place completely online using a computer, smartphone, or tablet.
Geisinger Health System is an integrated health services organization recognized for its innovative use of the electronic health record (EHR), and the development of new care models such as ProvenHealth Navigator and ProvenCare.
Related Links:
Clinical Genome Resource
US National Institutes of Health
GenomeConnect patient portal
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
Multiple myeloma is an incurable cancer of the bone marrow, and while many patients now live for more than a decade after diagnosis, a significant proportion relapse much earlier with poor outcomes.... Read more
Compact Raman Imaging System Detects Subtle Tumor Signals
Accurate cancer diagnosis often depends on labor-intensive tissue staining and expert pathological review, which can delay results and limit access to rapid screening. These conventional methods also make... Read moreMolecular Diagnostics
view channel
Blood Metabolite Signature Test Better Predicts Type 2 Diabetes Risk
Type 2 diabetes is rising worldwide and now accounts for more than 90% of all diabetes cases, driven by impaired insulin response and long-term metabolic dysfunction. The disease often develops silently... Read more
Genetic Test Could Detect Predisposition to Pancreatic Cancer
Pancreatic ductal adenocarcinoma is one of the deadliest cancers, largely because it is usually diagnosed at an advanced stage when treatment options are limited. The lack of effective population screening... Read moreHematology
view channel
AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
Alpha thalassemia affects millions of people worldwide and is especially common in regions such as Southeast Asia, where carrier rates can reach extremely high levels. While the condition can have significant... Read more
MRD Tests Could Predict Survival in Leukemia Patients
Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read moreImmunology
view channel
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
New Test Measures How Effectively Antibiotics Kill Bacteria
Antibiotics are typically evaluated by how well they inhibit bacterial growth in laboratory tests, but growth inhibition does not always mean the bacteria are actually killed. Some pathogens can survive... Read more
New Antimicrobial Stewardship Standards for TB Care to Optimize Diagnostics
Antibiotic resistance is rising worldwide, threatening the effectiveness of treatments for major infectious diseases, including tuberculosis (TB). Resistance to key TB drugs, such as bedaquiline, is of... Read morePathology
view channel
Intraoperative Tumor Histology to Improve Cancer Surgeries
Surgical removal of cancer remains the first-line treatment for many tumors, but ensuring that all cancerous tissue is removed while preserving healthy tissue is a major challenge. Surgeons currently rely... Read more
Rapid Stool Test Could Help Pinpoint IBD Diagnosis
Inflammatory bowel disease (IBD) is a chronic condition in which the immune system mistakenly attacks the digestive tract, causing persistent gut inflammation. Diagnosis and disease monitoring often depend... Read more
AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery
Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read moreTechnology
view channelAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channel
WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
World Health Expo (WHX) Labs in Dubai (formerly Medlab Middle East), which will be held at Dubai World Trade Centre from 10-13 February, will address the growing global threat of antimicrobial resistance... Read more







